$CDXC NAD Revolution | Niagen’s Role in Redefining Aging and Wellness | TickerTrends.io

The TickerTrends Social Arbitrage Hedge Fund is currently accepting capital. If you are interested in learning more send us an email admin@tickertrends.io . Join our Discord here for more discussion.

Nov 21, 2024

∙ Paid

Business Intro:

ChromaDex Corporation, based in Los Angeles, California, is a global bioscience company at the forefront of healthy aging innovation. Since its founding in 2000, ChromaDex has grown from a provider of analytical reference standards and services into a recognized leader in the research, development, and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors. NAD+ is an essential coenzyme that declines with age and plays a critical role in cellular energy production and overall health. ChromaDex's flagship ingredient, Niagen®, is a proprietary form of nicotinamide riboside (NR), a novel vitamin B3 derivative that is clinically proven to increase NAD+ levels in the body. Supported by over 275 research collaborations with prestigious institutions like Harvard, MIT, and the National Institutes of Health, and more than 375 peer-reviewed studies, ChromaDex has established itself as a scientific leader in this emerging field.

The company operates through three core business segments: consumer products, ingredients, and analytical services. Its consumer product line, Tru Niagen®, is a widely acclaimed supplement designed to boost NAD+ levels and promote healthy aging. Distributed directly through e-commerce platforms such as Amazon and TruNiagen.com, as well as in partnership with international retailers, Tru Niagen® is available in over 100 countries, underpinned by a reputation for scientific rigor and efficacy. ChromaDex also supplies food-grade and pharmaceutical-grade Niagen® as raw materials to industry-leading partners, including Nestlé, enabling the integration of its technology into a variety of health and wellness products. Additionally, the company offers high-quality analytical services and phytochemicals to ensure the safety and quality of dietary supplements and other consumer goods.

In recent years, ChromaDex has expanded its reach into pharmaceutical applications with the launch of Niagen Plus, which includes pharmaceutical-grade IV and injectable formulations designed for anti-aging and wellness clinics. This product line has gained significant traction, bolstered by its ability to deliver higher bioavailability compared to traditional supplements. The company’s strategic partnerships and regulatory approvals in key markets further enhance its ability to capture growing global demand for NAD+ boosting solutions. With a strong financial foundation, including consistent revenue growth and positive cash flow, ChromaDex is well-positioned to capitalize on the rapidly expanding health and wellness industry, projected to grow significantly over the next decade. By combining cutting-edge science, innovative products, and strategic market execution, ChromaDex continues to lead the NAD+ space while advancing its mission to improve global health and longevity.